This research demonstrates a novel biosensor that rapidly detects TNF‐α in saliva, suggesting improved diabetes management.
Tumor necrosis factor‐ α (TNF‐ α ) has emerged as a critical biomarker for insulin resistance and diabetic complications, offering an alternative avenue for diabetes management beyond conventional glucose monitoring. Current methods for detecting TNF‐ α are constrained by their complexity and lack of adaptability for home‐based use. We present a novel conductometric sensor engineered for highly sensitive, selective, and rapid detection (<2 min) of TNF‐ α in saliva. Developed through surface modification of high‐resistivity silicon wafers, the sensor achieves quantification of TNF‐ α in the femtomolar range with the limit of detection as low as 10 fM which is 100× times lower than that of critical concentration of TNF‐ α in saliva and demonstrates robust performance under varying pH conditions. The ultrahigh sensitivity for TNF‐ α demonstrates the capability for effective prescreening method of diabetes and the demonstration of robust linear sensor response between the clinically relevant salivary TNF‐ α levels illustrates its use for practical diabetes monitoring. Leveraging a Bluetooth microcontroller, the sensor integrates wireless data transmission to a smartphone, enabling rapid and user‐friendly monitoring. This technology represents a significant advancement in TNF‐ α detection, offering a holistic approach to track disease progression and complications, with the potential to transform the early identification and monitoring of diabetic conditions.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: